08:55 AM EST, 01/07/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) reported "statistically significant" topline results Tuesday from a phase 3 study evaluating the combination of Rybrevant and Lazcluze as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.

The pharmaceutical company said the combination regimen, which avoids the use of chemotherapy, met the final pre-specified secondary endpoint of overall survival.

It also said the trial demonstrated "clinically meaningful and statistically significant" improvement in overall survival compared with AstraZeneca's ( AZN ) osimertinib, which it said is the current standard of care.